Targeting TRAIL towards the clinic

Current Drug Targets

Volumn 12, Issue 14, 2011, Pages 2079-2090

  Mahalingam, Devalingam ^a,b   Oldenhuis, Corina N A M ^b   Szegezdi, Eva ^c   Giles, Francis J ^a   de Vries, Elisabeth G E ^b   de Jong, Steven ^b   Nawrocki, Steffan T ^a  

^a University of Texas Health Science Center at San Antonio   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Apoptosis; Cancer; DcR1; DcR2; DR4; DR5; TRAIL and clinical trials

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CONATUMUMAB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DOXORUBICIN; DROZITUMAB; DULANERMIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; RITUXIMAB; SORAFENIB; TIGATUZUMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ABDOMINAL PAIN; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; APOPTOSIS; ARTHRALGIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CELL CYCLE ARREST; CHILL; CHONDROSARCOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DNA DAMAGE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; DRUG TARGETING; DYSPNEA; EPISTAXIS; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HERPES ZOSTER; HUMAN; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; IMMUNOHISTOCHEMISTRY; LIVER CARCINOMA; LIVER METASTASIS; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NUCLEAR LOCALIZATION SIGNAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; PRURITUS; REVIEW; RHINITIS; RHINORRHEA; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTOPENIA; TISSUE MICROARRAY; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROGNOSIS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855846945     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798829357     Document Type: Review

References (138)

1. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998; 281(5381): 1305-8.
2. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271(22): 12687-90.
3. Mariani SM, Krammer PH. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998; 28(3): 973-82.
4. Wajant H, Moosmayer D, Wuest T, et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20(30): 4101-6.
5. Mahalingam D, Szegezdi E, Keane M, Jong S, Samali A. TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treatment Rev 2009; 35(3): 280-8.
6. Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001; 31(11): 3138-46.
7. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168(3): 1356-61.
8. Song K, Chen Y, Goke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191(7): 1095-104.
9. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001; 166(2): 1314-9.
10. Sedger LM, Shows DM, Blanton RA, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163(2): 920-6.
11. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 2001; 193(6): 661-70.
12. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189(9): 1451-60.
13. Sedger LM, Glaccum MB, Schuh JC, et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 2002; 32(8): 2246-54.
14. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277(5327): 815-8.
15. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998; 424(1-2): 41-5.
16. Degli-Esposti MA, Smolak PJ, Walczak H, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186(7): 1165-70.
17. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997; 7(6): 813-20.
18. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273(23): 14363-7.
19. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAILdependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000; 12(6): 611-20.
20. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12(6): 599-609.
21. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388(6638): 190-5.
22. Eskes R, Desagher S, Antonsson B, Martinou JC. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000; 20(3): 929-35.
23. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membranetargeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14(16): 2060-71.
24. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281(5381): 1322-6.
25. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102(1): 1-4.
26. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001; 6(4): 253-61.
27. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nature Rev 2002; 3(6): 401-10.
28. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102(1): 33-42.
29. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102(1): 43-53.
30. Mahalingam D, Keane M, Pirianov G, et al. Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines. Br J Cancer 2009; 100(9): 1415-24.
31. Hu WH, Johnson H, Shu HB. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999; 274(43): 30603-10.
32. Secchiero P, Gonelli A, Carnevale E, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003; 107(17): 2250-6.
33. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P. Activation of ERK1/2 protects melanoma cells from TRAILinduced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003; 22(19): 2869-81.
34. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281(5383): 1680-3.
35. Lin Y, Devin A, Cook A, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000; 20(18): 6638-45.
36. Bode AM, Dong Z. The functional contrariety of JNK. Mol Carcinog 2007; 46(8): 591-8.
37. Yu C, Minemoto Y, Zhang J, et al. JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 2004; 13(3): 329-40.
38. Maundrell K, Antonsson B, Magnenat E, et al. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 1997; 272(40): 25238-42.
39. Soderstrom TS, Poukkula M, Holmstrom TH, Heiskanen KM, Eriksson JE. Mitogen-activated protein kinase/extracellular signalregulated kinase signaling in activated T cells abrogates TRAILinduced apoptosis upstream of the mitochondrial amplification loop and caspase-8. J Immunol 2002; 169(6): 2851-60.
40. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001; 276(19): 16484-90.
41. Lee TJ, Lee JT, Park JW, Kwon TK. Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun 2006; 351(4): 1024-30.
42. Panner A, James CD, Berger MS, Pieper RO. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005; 25(20): 8809-23.
43. Karin M. The beginning of the end: IkappaB kinase (IKK) and NFkappaB activation. J Biol Chem 1999; 274(39): 27339-42.
44. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289(5484): 1550-4.
45. Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001; 20(29): 3888-96.
46. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20(8): 2687-95.
47. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NFkappaB. Immunity 1997; 7(6): 831-6.
48. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7(6): 821-30.
49. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5(5): 417-21.
50. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 331(3): 851-8.
51. Bedi A, Mookerjee B. Biological significance and molecular mechanisms of p53-induced apoptosis. Apoptosis 1998; 3(4): 237-44.
52. Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001; 188(1): 98-105.
53. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNAbinding site. Oncogene 2000; 19(14): 1735-43.
54. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004; 64(15): 5078-83.
55. Sheikh MS, Huang Y, Fernandez-Salas EA, et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damageinducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene 1999; 18(28): 4153-9.
56. Meng RD, McDonald ER, 3rd, Sheikh MS, Fornace AJ, Jr., El-Deiry WS. The TRAIL decoy receptor TRUNDD (DcR2, TRAILR4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther 2000; 1(2): 130-44.
57. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59(3): 734-41.
58. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97(4): 1754-9.
59. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001; 61(2): 759-63.
60. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor necrosis factorrelated apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004; 64(14): 4900-5.
61. Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and-independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998; 58(8): 1593-8.
62. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 2004; 61(1): 35-49.
63. Hirsch FR, Varella-Garcia M, Cappuzzo F. Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer. Oncogene 2009; 28(Suppl 1): S32-7.
64. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235(4785): 177-82.
65. Younes M, Georgakis GV, Rahmani M, Beer D, Younes A. Functional expression of TRAIL receptors TRAIL-R1 and TRAILR2 in esophageal adenocarcinoma. Eur J Cancer 2006; 42(4): 542-7.
66. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNFrelated apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000; 164(8): 3961-70.
67. Melloni E, Secchiero P, Celeghini C, et al. Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. J Cell Physiol 2005; 204(3): 975-82.
68. Koornstra JJ, Kleibeuker JH, van Geelen CM, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003; 200(3): 327-35.
69. Ryu HS, Chang KH, Chang SJ, Kim MS, Joo HJ, Oh KS. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int J Gynecol Cancer 2000; 10(5): 417-24.
70. Reesink-Peters N, Hougardy BM, van den Heuvel FA, et al. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 2005; 96(3): 705-13.
71. Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 2004; 92(3): 794-800.
72. Spierings DC, de Vries EG, Vellenga E, et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004; 52(6): 821-31.
73. van Geelen CM, Westra JL, de Vries EG, et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006; 24(31): 4998-5004.
74. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005; 11(14): 5188-94.
75. Kuijlen JM, Mooij JJ, Platteel I, et al. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 2006; 78(2): 161-71.
76. Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAILtargeted therapy of malignancy. J Clin Oncol 2007; 25(28): 4505-6.
77. Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer 2006; 42(14): 2233-40.
78. Szegezdi E, Cahill S, Meyer M, O'Dwyer M, Samali A. TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt. Br J Cancer 2006; 94(3): 398-406.
79. Ganten TM, Haas TL, Sykora J, et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004; 11(Suppl 1): S86-96.
80. Sayers TJ, Brooks AD, Koh CY, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003; 102(1): 303-10.
81. Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64(10): 3517-24.
82. Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptormediated apoptosis. Oncogene 2000; 19(48): 5477-86.
83. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21(15): 2283-94.
84. Hao JH, Yu M, Liu FT, Newland AC, Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res 2004; 64(10): 3607-16.
85. Hougardy BM, Maduro JH, van der Zee AG, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 2006; 118(8): 1892-900.
86. Guo F, Sigua C, Tao J, et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64(7): 2580-9.
87. Vasilevskaya IA, O'Dwyer PJ. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol 2005; 70(4): 580-9.
88. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosisinducing ligand. Nat Med 2000; 6(5): 564-7.
89. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7(4): 383-5.
90. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104(2): 155-62.
91. Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60(3): 553-9.
92. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003; 171(3): 1526-33.
93. Leverkus M, Sprick MR, Wachter T, et al. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Molec Cell Biol 2003; 23(3): 777-90.
94. Ashkenazi A. Targeting death and decoy receptors of the tumournecrosis factor superfamily. Nat Rev Cancer 2002; 2(6): 420-30.
95. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7(8): 954-60.
96. Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factorrelated apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280(3): 2205-12.
97. van der Sloot AM, Tur V, Szegezdi E, et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006; 103(23): 8634-9.
98. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpharelated apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004; 64(11): 3922-7.
99. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5(5): 501-12.
100. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAILR1 in primary lymphoid malignancies. Cancer Res 2005; 65(24): 11265-70.
101. van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer 2000; 89(2): 363-73.
102. Lee H-W, Lee S-H, Lee H-W, Ryu Y-W, Kwon M-H, Kim Y-S. Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem Biophys Res Commun 2005; 330(4): 1205-12.
103. Clancy L, Mruk K, Archer K, et al. Preligand assembly domainmediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102(50): 18099-104.
104. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26(19): 7046-55.
105. Herbst RS, Mendolson DS, Ebbinghaus S, et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24(18S)(20 Suppl): p. 3013.
106. Ling J HR, Mendelson DS, Eckhardt SG, et al. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24(18S)(20 Suppl): p. 3047.
107. Fanale M, Burris H, Yee L, et al. Results of a phase Ib study of recombinant human Apo2L/TRAIL with rituximab in patients with relapsed, low-grade NHL. Ann Oncol 2008; 19(Suppl 4): 258.
108. Soria J, Smit E, Khayat D, et al. Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(20 Suppl) Abstr 3539.
109. Soria JC, Smit E, Khayat D, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 1998; 28(9): 1527-33.
110. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factorrelated apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25(11): 1390-5.
111. Hotte SJ, Hirte HW, Chen EX, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14(11): 3450-5.
112. Kanzler S, Trarbach T, Heinemann V, et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC). Eur J Cancer 2005; 3(Suppl) Abstr 630: 177.
113. Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2008; 61(1): 82-90.
114. Younes A, Vose JM, Zelenetz AD, et al. Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood 2005; 106: 489.
115. Mom CH, Verweij J, Oldenhuis CN, et al. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 2009; 15(17): 5584-90.
116. Leong S, Cohen RB, Gustafson DL, et al. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J Clin Oncol 2009; 27(26): 4413-21.
117. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13(20): 6187-94.
118. Wakelee HA, Patnaik A, Sikic BI, et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2009; doi: 101093/annonc/mdp292.
119. Camidge D, Herbst RS, Gordon M, et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(18S)(20 Suppl), p. 3582.
120. http://wwwclinicaltrialsgov/ct2/show/NCT00543712?term=PRO 95780&rank. accessed October 2009.
121. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(18S) (20 Suppl): p. 3534.
122. Saleh MN, Percent I, Wood TE, et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. J Clin Oncol 2008; (20 Suppl): Abstr 3537.
123. Sikic BI, Wakelee HA, von Mehren M, et al. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(18S)(20 Suppl): p. 14006.
124. Rougier P, Infante J, van Laethem J, et al. A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results. J Clin Oncol 2009; 27: 15s
125. Kindler HL, Garbo L, Stephenson J, et al. A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC) J Clin Oncol 2009; 27: 15s.
126. Saltz L IJ, Schwartzberg L, Stephenson J, et al. Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2009; 27: 15s.
127. Paz-Ares L, Sánchez Torres JM, Diaz-Padilla I, et al. Safety and efficacy of AMG 655 in combination with paclitaxel and carboplatin (PC) in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27: Abstr e19048.
128. de Vries EG, de Jong S. Exploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run. J Clin Oncol 2008; 26(32): 5151-3.
129. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5(1): 25-35.
130. Dean E, Jodrell D, Connolly K, et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 2009; 27(10): 1660-6.
131. Talbot DC, Callies S, Andre V, et al. First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. J Clin Oncol 2008; 26(20 Suppl): Abstr 3518.
132. Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26(32): 5198-203.
133. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24(29): 4738-45.
134. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25(9): 1114-20.
135. O'Brien SM, Claxton DF, Crump M, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113(2): 299-305.
136. Schimmer AD, O'Brien S, Kantarjian H, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14(24): 8295-301.
137. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15(9): 3172-6.
138. Wilson WH, Czuczman MS, LaCasce AS, et al. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. J Clin Oncol 2008; 26(20 Suppl): Abstr 8511.